Abstract 19552: High Igm Levels Are Inversely Associated With Necrotic Core Assessed by Ivus but Do Not Predict Plaque Progression: Results of the Ibis-3 Study
Introduction: Atherosclerosis is a chronic inflammatory disease which involves both the innate and adaptive immune systems. We investigated whether immunoglobulin (Ig) levels and Igs against a specific epitope of oxidized LDL (malondialdehyde-conjugated low-density lipoprotein (MDA-LDL)), correlate with the development of coronary atherosclerotic plaque and necrotic core in patients undergoing coronary angiography.
Methods: IBIS-3 was a prospective cohort study that evaluated the effect of one year of high dose rosuvastatin (goal 40mg/day) on the necrotic core. Patients undergoing CAG or PCI for (un)stable angina pectoris or myocardial infarction were eligible. After the standard procedure, RF-IVUS measurements were performed in a non-culprit coronary artery with a diameter stenosis <50%. After a median of 386 days of high dose rosuvastatin treatment, IVUS measurements of the same segment were repeated. Linear regression was used for analyses.
Results: Between 2010-2013, 143 patients were included. Median age was 60.1 (IQR 55.2, 65.7) years and 84.6% were men. At baseline and follow up, the visualized segments had a median plaque burden of 40.5 and 40.9% with a necrotic core percentage of 19.9 and 19.6% respectively. Multivariate analysis showed that baseline levels of IgM and IgM anti MDA-LDL were inversely associated with percentage of necrotic core. A doubling of IgM or IgM MDA-LDL antibodies was on average associated with a decrease in necrotic core of 5.17 and 2.99 percent, respectively. None of the biomarkers were associated with plaque or plaque progression. Average IVUS-values and the p-values derived from the linear regression models are presented in table 1.
Conclusion: IgM and IgM MDALDL antibody levels were inversely associated with baseline necrotic core percentage, but not plaque burden. None of the investigated Igs were associated with progression of necrotic core or plaque burden after a year of high dose rosuvastatin treatment.
Author Disclosures: V.J. van den Berg: None. R. Khamis: None. I. Kardys: None. E. Regar: None. R.J. van Geuns: None. N. van Mieghem: None. P.W. Serruys: None. V.A. Umans: None. K.M. Akkerhuis: None. D. Haskard: None. E. Boersma: None.
- © 2016 by American Heart Association, Inc.